Provided by Tiger Trade Technology Pte. Ltd.

Incyte

121.47
-1.8100-1.47%
Post-market: 119.64-1.8334-1.51%19:30 EDT
Volume:1.43M
Turnover:173.96M
Market Cap:24.62B
PE:15.47
High:124.35
Open:124.35
Low:121.42
Close:123.28
52wk High:132.60
52wk Low:81.09
Shares:202.70M
Float Shares:169.82M
Volume Ratio:1.19
T/O Rate:0.84%
Dividend:- -
Dividend Rate:- -
EPS(TTM):7.85
EPS(LYR):6.41
ROE:30.67%
ROA:16.83%
PB:3.88
PE(LYR):18.95

Loading ...

Pharma Sector Doubles Down on AI Amid Hopes of Slashing Costs, Timelines

Reuters
·
Aug 20

Incyte : Canaccord Genuity Initiates Coverage with Buy Rating; Price Target $152

THOMSON REUTERS
·
Aug 20

Incyte Price Target Maintained with a $150.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 20

Canaccord Genuity Initiates Incyte at Buy With $152 Price Target

MT Newswires Live
·
Aug 20

Incyte Corp. Stock Underperforms Wednesday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Aug 20

Matt Phipps Maintains Hold Rating on Incyte as Promising Early KRAS G12D PDAC Data Face Durability and Safety Uncertainties

TIPRANKS
·
Aug 20

Incyte ‘734 update likely to be ‘very competitive,’ says RBC Capital

TIPRANKS
·
Aug 19

Incyte Corp. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Aug 18

Incyte is Maintained at Overweight by Piper Sandler

Dow Jones
·
Aug 18

Piper Sandler Adjusts Price Target on Incyte to $130 From $110, Maintains Overweight Rating

MT Newswires Live
·
Aug 17

Incyte : Piper Sandler Raises Target Price to $130 from $110

THOMSON REUTERS
·
Aug 17

Incyte Earnings Call: Growth Surges, Costs Climb

TIPRANKS
·
Aug 15

Incyte President, Global Head of R&D Pablo J. Cagnoni Sells 10,803 Shares for $1.3 Million

Reuters
·
Aug 15

Bernstein Adjusts Price Target on Incyte to $104 From $99, Keeps Market Perform Rating

MT Newswires Live
·
Aug 13

Incyte Grants 24 New Hires 21,556 RSUs and 18,172 Stock Options Priced at USD 118.43

Reuters
·
Aug 08

Incyte EVP, Chief Scientific Officer Patrick Mayes Sells 2,207 Shares for $273,447.93

Reuters
·
Aug 08

Incyte Corp. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Aug 07

Incyte’s EXCALIBUR-ET2 Trial Targets a New Edge in Essential Thrombocythemia

TIPRANKS
·
Aug 07

Top Incyte Insiders Quietly Cash In On Major Stock Sale

TIPRANKS
·
Aug 05

Incyte Corp. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Aug 05